| (i) A patient with advanced, progressive non-small-cell lung cancer, lymphangiosis carcinomatosa, |
| multiple metastases and pericardial effusion who had undergone prior palliative chemotherapies |
| developed massive shortness of breath and pain. Her previous intravenous infusions with Iscador were |
| changed to Helixor. Her condition unexpectedly improved drastically. She was able to go home and |
| lived well for 3 more months. After a fall and injury, her condition deteriorated and she died. (General practitioner) |
| (ii) A patient with plasmocytoma received weekly infusions (Helixor P, 100–300 mg), inducing fever (38-39°C). |
| Her condition and protein levels improved and became stable. The proteins later increased again, and a |
| fever reaction could no longer be induced. Infusions were changed to an Abnoba preparation with high- |
| dose intravenous (40–80 mg) and subcutaneous (10 mg) application. For 3 years, up to the interview, |
| the patient was in good condition, was working and lived a very active life. (Average survival in untreated |
| plasmocytoma is 3.5 years). (Internist) Another doctor described the stabilization of condition and bone |
| manifestations in advanced plasmocytoma for periods of 6-7 years under regular mistletoe infusions. (Oncologist) |
| (iii) A patient with colon cancer and extensive liver metastases was expected to die soon. Different |
| mistletoe applications had made no difference. Mistletoe infusion was combined with Helleborus niger, |
| which was followed by a stabilization of the disease for several months with good QoL. (Internist) |
